Vimarsana
Biggest News Aggregation in the World

Nir Naor News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Nir Naor. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Nir Naor Today - Breaking & Trending Today

AxoGen, Inc. (NASDAQ:AXGN) Q1 2024 Earnings Call Transcript - Vimarsana News

AxoGen, Inc. (NASDAQ:AXGN) Q1 2024 Earnings Call Transcript

Operator: Greetings, and welcome to the AxoGen, Inc. 2024 First Quarter Financial Results Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded.

Axogen Names Nir Naor Chief Financial Officer - Vimarsana News

Axogen Names Nir Naor Chief Financial Officer

By Colin Kellaher Axogen has named Nir Naor chief financial officer of the surgical-solutions company. Axogen on Wednesday said Naor, 49 years old, succeeds...

Axogen Announces Transition of Finance Team Leadership - Vimarsana News

Axogen Announces Transition of Finance Team Leadership

Nir Naor Appointed CFO to Replace Peter Mariani as Company Aligns Executive Team with Financial Management Needs for Next Phase of GrowthALACHUA, Fla. and TAMPA, Fla., Dec. 06, 2023 -- Axogen, Inc....

BrainStorm Cell Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update - Vimarsana News

BrainStorm Cell Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update

FDA advisory committee meeting to discuss NurOwn® for Amyotrophic Lateral Sclerosis scheduled for September 27, 2023 BrainStorm's Biologics License Application for NurOwn has a Prescription... -Today at 07:06 am- MarketScreener

BrainStorm Cell Therapeutics Appoints Nir Naor as Board Member and Audit Committee Chair - Vimarsana News

BrainStorm Cell Therapeutics Appoints Nir Naor as Board Member and Audit Committee Chair

NEW YORK, June 20, 2023 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. , a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the appointment... | June 20, 2023